Craig Hallum Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals (NASDAQ:ETON) had its price target boosted by equities research analysts at Craig Hallum from $15.00 to $18.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s target price would indicate a potential upside of 49.88% from the company’s current price.

Separately, HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday.

Eton Pharmaceuticals Price Performance

ETON stock opened at $12.01 on Wednesday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The business has a 50-day moving average price of $11.64 and a 200 day moving average price of $7.35. The company has a market capitalization of $312.87 million, a P/E ratio of -54.59 and a beta of 1.38.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC acquired a new stake in Eton Pharmaceuticals in the second quarter valued at approximately $3,095,000. Wasatch Advisors LP acquired a new stake in shares of Eton Pharmaceuticals in the 3rd quarter worth $1,431,000. Aristides Capital LLC acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter worth $658,000. Thompson Siegel & Walmsley LLC purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth $420,000. Finally, Stonepine Capital Management LLC acquired a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $362,000. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.